| sess_SDA-2026-04-25- | Does C1q function differ based on subcellular localization or binding partner id | 0.68 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-afba1a80bd |
| sess_SDA-2026-04-25- | Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects | 0.63 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-18cce7b525 |
| sess_SDA-2026-04-25- | Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate bas | 0.74 | 5 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-9180363b7c |
| sess_SDA-2026-04-25- | Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retenti | 0.58 | 6 | 4 | completed | 2026-04-25 | SDA-2026-04-25-gapdebate-f4c8357045 |
| sess_aging-mouse-bra | How does gene expression change across age groups (young/middle/old) in hippocam | 1.00 | 3 | 4 | completed | 2026-04-24 | aging-mouse-brain-2026-04-02 |
| pan_0b9f67e3 | is the amyloid cascade hypothesis still important | 0.50 | 0 | 0 | completed | 2026-04-24 | |
| pan_5d0f52d1 | Is the amyloid hypothesis still tractable for AD? | 0.50 | 0 | 0 | completed | 2026-04-24 | |
| sess_hyp_h-b2aeabb1_ | Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strat | 0.76 | 0 | 4 | completed | 2026-04-23 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| sess_hyp_SDA-2026-04 | Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to | 0.81 | 0 | 4 | completed | 2026-04-23 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| target_debate_t-2a37 | Should MAPT (None) be prioritized as a therapeutic target for neurodegeneration? | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should PIEZO1ANDKCNK2 (PIEZO1ANDKCNK2) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CELL-TYPE-SPECIFICESSENTIALGENES (CELL-TYPE-SPECIFICESSENTIALGENES) be pr | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SIRT3 (NAD-dependent deacetylase sirtuin-3, mitochondrial) be prioritized | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should AADC (Aromatic L-amino acid decarboxylase) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CHRNA7 (CHRNA7 Protein) be prioritized as a therapeutic target for neurod | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GPR109A (Hydroxycarboxylic Acid Receptor 2 (HCAR2)) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MAP6 (Microtubule-associated protein 6) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GFAP (Glial fibrillary acidic protein) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should ST3GAL2 (ST3 beta-galactoside alpha-2,3-sialyltransferase 2) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MTOR (Mechanistic Target of Rapamycin) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CSGA (CSGA Protein) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CNO (Cappuccino) be prioritized as a therapeutic target for neurodegenera | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CHMP4B (Charged multivesicular body protein 4B) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SLC16A2 (Monocarboxylate transporter 8) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CLDN1 (Claudin-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CLDN5 (Claudin-5) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should ST8SIA1 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1) be | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should BRD4 (Bromodomain-containing protein 4) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should LOXL1-4 (Lysyl oxidase-like 1-4) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should CAV1 (Caveolin-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should FLOT1 (Flotillin 1) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should AQP4 (Aquaporin-4) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SGMS1 (Sphingomyelin synthase 1) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SIRT1 (NAD-dependent protein deacetylase sirtuin-1) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should GAP43 (Growth associated protein 43) be prioritized as a therapeutic targ | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should FUT8 (Alpha-(1,6)-fucosyltransferase) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should MCU (Mitochondrial calcium uniporter) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SGMS2 (Sphingomyelin synthase 2) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should RELN (Reelin) be prioritized as a therapeutic target for neurodegeneratio | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should SNAP25 (Synaptosome associated protein 25) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-23 | |
| target_debate_target | Should PLA2G6 (Phospholipase A2 group VI) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SETX (Senataxin) be prioritized as a therapeutic target for neurodegenera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should FOXP3 (Forkhead box protein P3) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CHR2 (Channelrhodopsin-2) be prioritized as a therapeutic target for neur | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SYNCRIP (Heterogeneous nuclear ribonucleoprotein Q) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should DGAT1 (Diacylglycerol O-Acyltransferase 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should HSPG2 (Heparan Sulfate Proteoglycan 2) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PLIN2 (Perilipin 2) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ST6GAL1 (ST6 beta-galactoside alpha-2,6-sialyltransferase 1) be prioritiz | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should PYCARD (Apoptosis-associated speck-like protein containing CARD) be prior | 0.50 | 0 | 4 | completed | 2026-04-22 | |